YH34160 / Yuhan Corp - LARVOL DELTA

YH34160, a Novel Long-Acting GDF15 Fusion Protein, Exerts Potent and Sustained Body Weight Loss in Rodent Obesity Models (ADA 2022) - "Interestingly, YH34160 in combination with GLP-1RA or dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist (GIPRA) achieved more potent and greater BW loss compared to each mono-treated group. Overall, these findings indicate that YH34160 would be a promising therapeutic candidate, as well as in combination with GLP-1-based therapeutics, for the treatment of obesity and obesity-related comorbidities."

Late-breaking abstract • Preclinical • Leptin Receptor Deficiency Obesity • Metabolic Disorders • Obesity • GDF15 • LEP